Clinical Trial Update: Bioequivalence With Clinical Endpoint Study of Fluticasone Propionate 100 mcg and Salmeterol 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 100/50 mcg Inhalation Powder/GSK in Patients With Asthma [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating bioequivalence with a clinical endpoint for fluticasone propionate/salmeterol inhalation powder versus Advair Diskus in asthma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• Advair Diskus 100/50 mcg Inhalation Powder (Fluticasone Propionate/Salmeterol)
• Fluticasone Propionate 100 mcg / Salmeterol 50 mcg Inhalation Powder

Snippet

Sponsor: Respirent Pharmaceuticals Co Ltd. | Conditions: Asthma | Phase 3 | Status: UNKNOWN